Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Management and Treatment of Hepatitis C Viral Infection: Table 6

for Health Care Providers

Table 6. Comparison of Sustained Virologic Response (SVR) Rates for Peginterferon Alfa-2a Combination Therapy, Peginterferon Alfa-2a Monotherapy, and Interferon Alfa Combination Therapy Given Over 48 wk

Table 6. Comparison of Sustained Virologic Response (SVR) Rates for Peginterferon Alfa-2a Combination Therapy, Peginterferon Alfa-2a Monotherapy, and Interferon Alfa Combination Therapy Given Over 48 wk (14)
*peginterferon alfa-2a 180 mcg/week plus ribavirin 1,000 or 1,200 mg/day

peginterferon alfa-2a 180 mcg/week plus placebo

IFN 3 million U three times/week plus ribavirin 1,000 or 1,200 mg/day

§Compared to interferon alfa plus ribavirin

**Defined as >2 million copies/mL (COBAS AMPLICOR HCV Test, v. 2.0, sensitivity 100 copies/mL); equivalent to >800,000 IU/mL

Defined as ≤2 million copies/mL (COBAS AMPLICOR HCV Test, v. 2.0, sensitivity 100 copies/mL); equivalent to ≤800,000 IU/mL

PATIENT GROUPSVR
Peginterferon alfa-2A (40 kDa) plus ribavirin*Peginterferon alfa-2A (40 kDa) plus placeboInterferon alfa plus ribavirin
Overall56% (p<0.001)§29%44%
HCV genotype 146% (p<0.01)§21%36%
High viral
titer**
41%13%33%
Low viral
titer
56%39%43%
HCV genotype 2, 3 76% (p<0.01)45%61%
High viral
titer**
74%40%58%
Low viral
titer
81%58%65%